SG11202011963UA - Methods of use of cd24 for the prevention and treatment of graft versus host disease and mucositis - Google Patents

Methods of use of cd24 for the prevention and treatment of graft versus host disease and mucositis

Info

Publication number
SG11202011963UA
SG11202011963UA SG11202011963UA SG11202011963UA SG11202011963UA SG 11202011963U A SG11202011963U A SG 11202011963UA SG 11202011963U A SG11202011963U A SG 11202011963UA SG 11202011963U A SG11202011963U A SG 11202011963UA SG 11202011963U A SG11202011963U A SG 11202011963UA
Authority
SG
Singapore
Prior art keywords
mucositis
prevention
treatment
methods
host disease
Prior art date
Application number
SG11202011963UA
Inventor
Yang Liu
Pan Zheng
Martin Devenport
Original Assignee
Oncoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc filed Critical Oncoimmune Inc
Publication of SG11202011963UA publication Critical patent/SG11202011963UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
SG11202011963UA 2018-06-04 2019-06-03 Methods of use of cd24 for the prevention and treatment of graft versus host disease and mucositis SG11202011963UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862680218P 2018-06-04 2018-06-04
US201862739742P 2018-10-01 2018-10-01
US201862739719P 2018-10-01 2018-10-01
PCT/US2019/035200 WO2019236472A1 (en) 2018-06-04 2019-06-03 Methods of use of cd24 for the prevention and treatment of graft versus host disease and mucositis

Publications (1)

Publication Number Publication Date
SG11202011963UA true SG11202011963UA (en) 2020-12-30

Family

ID=68770596

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202011963UA SG11202011963UA (en) 2018-06-04 2019-06-03 Methods of use of cd24 for the prevention and treatment of graft versus host disease and mucositis
SG11202011964SA SG11202011964SA (en) 2018-06-04 2019-06-03 Methods of use of cd24 for the prevention and treatment of leukemia relapse

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202011964SA SG11202011964SA (en) 2018-06-04 2019-06-03 Methods of use of cd24 for the prevention and treatment of leukemia relapse

Country Status (15)

Country Link
US (2) US20210228680A1 (en)
EP (2) EP3802583A4 (en)
JP (2) JP2021527066A (en)
KR (2) KR20210018294A (en)
CN (2) CN112512640A (en)
AU (2) AU2019282530A1 (en)
BR (2) BR112020024683A2 (en)
CA (2) CA3102372A1 (en)
CL (2) CL2020003168A1 (en)
IL (2) IL279205A (en)
MA (2) MA52810A (en)
MX (2) MX2020013100A (en)
SG (2) SG11202011963UA (en)
TW (2) TW202015753A (en)
WO (2) WO2019236472A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020013100A (en) * 2018-06-04 2021-02-17 Oncoimmune Inc Methods of use of cd24 for the prevention and treatment of graft versus host disease and mucositis.
US20230108492A1 (en) * 2020-02-10 2023-04-06 Oncoimmune, Inc. Methods of use of soluble cd24 for treating viral pneumonia
WO2023205742A1 (en) * 2022-04-20 2023-10-26 OncoC4, Inc. Mutant cd24 proteins and uses thereof for prophylaxis and treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
WO2009063461A1 (en) 2007-11-14 2009-05-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using anti cd24 antibodies
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
PL3260128T3 (en) * 2010-04-28 2021-02-08 Oncoimmune, Inc. Medical use of soluble cd24
CN102250828B (en) * 2010-11-10 2014-11-05 北京大学 CD24 (glycosyl phosphatidyl inositol-linked surface mucin) and new use of CD24 antibody
WO2013158959A1 (en) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of graft-versus-host disease
WO2016073704A1 (en) 2014-11-06 2016-05-12 Children's Research Institute, Children's National Medical Center Immunotherapeutics for cancer and autoimmune diseases
CN107531772B (en) * 2015-05-07 2021-09-21 肿瘤免疫股份有限公司 Use of CD24 for reducing low density lipoprotein cholesterol levels
US10799558B2 (en) * 2016-02-02 2020-10-13 Oncoimmune, Inc. Use of CD24 proteins for treating leptin-deficient conditions
MX2020013100A (en) * 2018-06-04 2021-02-17 Oncoimmune Inc Methods of use of cd24 for the prevention and treatment of graft versus host disease and mucositis.
WO2021142336A1 (en) * 2020-01-08 2021-07-15 Puretech Lyt, Inc. Vesicle compositions for oral delivery

Also Published As

Publication number Publication date
CN112752766A (en) 2021-05-04
SG11202011964SA (en) 2020-12-30
IL279205A (en) 2021-01-31
EP3802583A4 (en) 2022-03-16
JP2021527056A (en) 2021-10-11
CA3102374A1 (en) 2019-12-12
EP3801773A4 (en) 2022-03-16
KR20210021317A (en) 2021-02-25
EP3802583A1 (en) 2021-04-14
US20210228680A1 (en) 2021-07-29
MA52811A (en) 2022-03-16
JP2021527066A (en) 2021-10-11
MX2020013100A (en) 2021-02-17
MX2020013103A (en) 2021-05-12
WO2019236472A1 (en) 2019-12-12
MA52810A (en) 2021-04-14
WO2019236474A1 (en) 2019-12-12
CL2020003168A1 (en) 2021-06-11
TW202015753A (en) 2020-05-01
US20210268061A1 (en) 2021-09-02
BR112020024659A2 (en) 2021-03-09
CN112512640A (en) 2021-03-16
US11911441B2 (en) 2024-02-27
CA3102372A1 (en) 2019-12-12
TW202012015A (en) 2020-04-01
KR20210018294A (en) 2021-02-17
IL279204A (en) 2021-01-31
AU2019282044A1 (en) 2021-01-07
AU2019282530A1 (en) 2021-01-07
CL2020003169A1 (en) 2021-06-11
EP3801773A1 (en) 2021-04-14
BR112020024683A2 (en) 2021-03-09

Similar Documents

Publication Publication Date Title
IL279204A (en) Methods of use of cd24 for the prevention and treatment of graft versus host disease and mucositis
IL276398A (en) Combination therapy for the treatment of mastocytosis
MX2020001774A (en) Compositions and methods for treating cholestatic disease.
IL268502A (en) Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease
SG11202012070YA (en) Methods and compositions for preventing or treating tissue calcification
EP3818085A4 (en) Compositions and uses thereof for treating disease or condition
EP3585818A4 (en) Anti-hla-dq2.5/8 antibody and its use for the treatment of celiac disease
IL269083A (en) Methods for preventing and treating heart disease
ZA202100092B (en) Modified cas9 protein and use thereof
IL284462A (en) Systems and methods for tissue treatment
IL261767A (en) Methods of treating or preventing graft versus host disease
IL275384A (en) Methods and compositions for pre-emptive treatment of graft versus host disease
BR112018012126A2 (en) "adjuvant, method for preventing and / or treating an autoimmune disease, and use of an adjuvant"
EP3740592A4 (en) Methods and compositions for the treatment of vascular disease
IL280589A (en) Compositions for the treatment of graft versus host disease
IL280638A (en) Fat tissue treatment
IL282904A (en) Therapeutic microbiota for the treatment and/or prevention of dysbiosis
EP3846843A4 (en) Compositions and methods for the treatment of heart disease
IL304675A (en) Compositions and methods for the treatment of graft versus host disease
GB2600026B (en) Intranasal epinephrine formulations and methods for the treatment of disease
IL279221A (en) Use of halogen compounds for the treatment and prevention of tissue injury and post-intensive care syndrome
GB2586577B (en) Diagnosis and treatment
RS64967B1 (en) Composition for use in the prevention and/or treatment of osteoarticular diseases
GB201820451D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
GB201806133D0 (en) Methods and medical uses